Integrative Analysis of DNA Methylation and Gene Expression Identified Follicular Thyroid Cancer-Specific Diagnostic Biomarkers

Yunjin Yao†, Peiwei Xu†, Tianxing Ying¹, Yue Wang¹, Xumeng Wang¹, Liqi Shu³, Zhe Mo², Zhijian Chen², Xiaofeng Wang², Weibin Wang¹*, Lisong Teng¹* and Xiaoming Lou²*

¹ Department of Surgical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, ² Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China, ³ Warren Alpert School of Medicine, Brown University, Providence, RI, United States

The diagnosis of follicular thyroid carcinoma (FTC) prior surgical resection remains a challenge, as routine screening methods, such as ultrasound or even FNAB, could not diagnose FTC preoperatively. Here, we performed an integrative analysis of DNA methylation and RNA array data from our own cohort (14 Follicular thyroid carcinoma vs 16 Benign thyroid lesion) to identify thyroid cancer-specific DNA methylation markers. We first identified differentially methylated and expressed genes and examined their correlations. Candidate DNA methylation sites were selected and further verified in validation set. Among all candidate methylation sites, cg06928209 was the most promising site as a molecular marker for early diagnosis, with a sensitivity of 90%, a specificity of 80% and an AUC of 0.77. Overall, our study demonstrates the potential use of methylation markers in FTC diagnosis and may boost the development of new epigenetic therapies.

Keywords: FTC, DNA methylation, diagnostic biomarker, gene expression profile (GEP), integrative "omics"

INTRODUCTION

Follicular cell-derived thyroid cancer is the most common endocrine malignancy. About 90-95% of thyroid cancers are follicular cell-derived and can be classified into differentiated thyroid cancers, including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC), poorly differentiated thyroid cancers and anaplastic thyroid cancers (1). Approximately 5% of clinically palpable thyroid nodules are thyroid cancers (2). Currently, fine needle aspiration biopsy (FNAB) is the gold standard for screening and diagnosis of thyroid nodules (3). Despite its high accuracy, approximately 17% of FNAB results are classified as indeterminate cytology (4). Subsequently, thyroideectomy is usually recommended while more than 60% of these resected nodules are ultimately diagnosed as non-malignant (4, 5), which means that more than half of those patients underwent unnecessary surgery and may require lifelong thyroid hormone replacement (6, 7).

Therefore, accurate preoperative diagnosis is important to improve the quality of patients’ life, yet the diagnosis of FTC has been a challenge, which requires postoperative pathologic evaluation (4).
Routine screening methods such as Ultrasound and FNAB have difficulties to distinguish FTC from benign thyroid nodules, especially follicular adenoma (2–4). Thus, there is an urgent need to advance the preoperative diagnostic tools for FTC.

Several molecular tests have been proposed to improve the accuracy of indeterminate FNAB cytology and avoid unnecessary or potentially harmful surgery for these patients. The investigation for genomic aberrations in FNAB, including BRAF and RAS point mutations, and PAX8/PPARγ and RET/PTC rearrangements have been explored (8). Recently, rare alterations described by next generation sequencing have also been reported to be diagnostically informative. Nevertheless, in many tumors these alterations are not observed, resulting in an elevated number of false-negative results (9–11). In the current era of molecular diagnostics, advanced methods are expected to continue to improve the diagnosis of thyroid nodules.

DNA methylation is considered to be a promising molecular marker for clinical testing, as DNA is more stable than RNA and proteins (12–14). Several studies have reported that some genes exhibit differential methylation in thyroid cancer, suggesting that these alterations may be useful in differentiating benign and malignant thyroid nodules (15–18). Based on the comparison of DNA methylation sites and RNA expression profiles between FTC and benign thyroid lesion (BTL) samples, our study intends to identify DNA methylation sites and their corresponding genes that are of greater clinical significance through the integrated analysis of the two results. Then potential molecular markers are identified to distinguish FTC and BTL.

MATERIALS AND METHODS

Study Cohort and Design

Thirty patients who underwent surgical resection of thyroid nodules in our medical center between 2016 to 2019 were randomly chosen in this study. All tissue samples were retrieved from formalin-fixed paraffin-embedded blocks and reviewed by an experienced attending pathologist. Among these samples, 10 were used as the discovery set, including 4 FTC and 6 BTL. And the rest were used as the external validation set, including 10 FTC and 10 BTL. Then, the DNA methylation profiles and RNA expression profiles of the samples in the discovery set were obtained by Illumina HumanMethylation850K array and Affymetrix Clariom S array respectively. Then, differential methylation and expression analyses were conducted, which were followed by integrative analysis of methylation sites and genes. Then, five methylation sites were identified and validated by Pyrosequencing in validation dataset. Figure 1 summarized the design of this study. The Institutional Ethics Committee approved the study. All thirty patients were advised and research informed consents were obtained.

RNA Differential Expression Analysis

Total RNA was extracted and purified using RecoverAllTM Total Nucleic Acid Isolation (Cat#AM1975, Ambion, Austin, TX, US) following the manufacturer’s instructions. Then, the total RNA was amplified, labeled and purified by Affymetrix WT PLUS Reagent Kit (Cat#902280, Affymetrix, Santa Clara, CA, US), Ovation FFPE WTA System (Cat#3403, NuGEN, San Carlos, CA, US) and FL-Ovation™ cDNA Biotin Module V2 (Cat#4200, NuGEN, San Carlos, CA, US). Array hybridization and washing was performed using GeneChip® Hybridization, Wash and Stain Kit (Cat#900720, Affymetrix, Santa Clara, CA, US) in a Hybridization Oven 645 (Cat#00-0331-220V, Affymetrix, Santa Clara, CA, US) and a Fluidics Station 450 (Cat#00-0079, Affymetrix, Santa Clara, CA, US). Arrays were scanned by Affymetrix GeneChip® Scanner 3000 (Cat#00-00213, Affymetrix, Santa Clara, CA, US) to obtain raw data. The raw data were normalized by Expression Console software of Affymetrix company. After normalization, the fold changes and p-values of different genes were calculated by the formula: foldchange = average (power (2, signal (FTC)))/average (power (2, signal (BTL))) and t-test separately. Differentially expressed genes (DEGs) were reported if the fold change was >2 or <0.5 and the p-value was smaller than 0.05. At last, Unsupervised consensus clustering was performed by R package “pheatmap” to obtain the heatmap of DEGs.

DNA Differential Methylation Analysis

DNA was isolated from the samples using OMEGA TISSUE DNA Kit according to the manufacturer’s instructions. DNA (500 ng) was treated with bisulfate using an EZ DNA Methylation Gold Kit (Zymo Research, Irvine, CA), according to the manufacturer’s instructions. The methylation of DNA was assayed on the Infinium MethylationEPIC BeadChip (Illumina, San Diego, CA) using the Illumina HD methylation assay kit from Shanghai Biotechnology Corporation.

DNA methylation data were analyzed using the methylation analysis module within BeadStudio software employing default parameters (Illumina, Inc., San Diego CA, USA). The raw intensity data were loaded to a bioconductor package “minfi” (version 1.25.1). The raw data were normalized using the subset-quantile within array normalization (SWAN) method and probes with a detection p-value over 0.01 in at least one sample were excluded from further analysis. Methylation values, referred to asβ-values, were calculated as the ratio of the methylated signal intensity to the sum of the methylated and unmethylated signals after background subtraction. The β-values were reported as a DNA methylation score ranging from 0 (completely unmethylated) to 1 (fully methylated). Differentially methylated sites were selected in IMA (version 3.1.2). In this study, we assessed the mean-difference β-value (Δβ) between the two sample groups for each site. Specifically, we considered a probe as differentially methylated if the absolute Δβ was higher than 0.1 and the statistical test was significant (p value <0.05).

Combination of Methylation Profiles and Expression Profile

On the basis of both expression profiling and DNA methylation differential analysis, DMs were annotated to specific genes by annotation table from Illumina website (downloaded from https://webdata.illumina.com/downloads/productfiles/
methylationEPIC/infinium-methylationepic-v-1-0-b5-manifest-file-bpm.zip), R package “ChAMP” and annotation information downloaded from UCSC Xena. Then we used function “merge” to match the DMSs to genes they located on. Specific locations of DMSs were also taken into consideration, where DMSs around the transcription start site (TSS) were more preferred. Since it is reported that DNA methylation is associated with gene silencing (19), DMSs with an inverse relationship between expression and methylation were of more interest. Genes’ information and background were also taken into consideration to select genes were interested in. Overall, five DMSs with a SNP distance over 10 bps and relatively large absolute Δβ were selected as candidate methylation sites.

**RESULTS**

**Basic Clinical Information of the Cohort**

This cohort included 12 males (40.0%) and 18 females (60.0%). The age distribution of the patients at the time of diagnosis ranged from 14 to 79 years, with a median of 52 years and a mean of 47.50 ± 16.12 years. As shown in Supplementary Table 1, all the FTC patients had no lymphatic metastases or distant metastases and only 2 of them were in stage II according to the 8th AJCC TNM staging system.

**Differentially Methylated Sites in FTC and BTL**

Of all 865,267 methylation sites compared between FTC and BTL, 13155 were differentially methylated. Among the differentially methylated sites, 6902 were hypermethylated in FTC and 6253 were hypomethylated in FTC. All the differentially methylated sites were displayed in volcano plot (Figure 2A). And a thousand of Sites with highest |Δβ| were included in heat-map (Figure 2C), which shows the samples were clearly separated into two groups in unsupervised consensus clustering. It means these Sites was promising in discriminating FTC from BTL.

**Differentially Expressed Genes in FTC and BTL**

Similarly, 31824 genes were compared between FTC and BTL, while 346 genes are differentially expressed, in which, 77 were over expressed in FTC and 269 were under expressed in FTC. All the differentially expressed genes were displayed in volcano plot (Figure 2B). All the differentially expressed genes were included in heatmap (Figure 2D), which shows the samples were
also clearly separated into two groups in unsupervised consensus clustering.

**Combination of Methylation Profiles and Expression Profile**

To identify DNA methylation changes with concomitant changes in gene expression, we integrated the gene expression profiles and DNA methylation profiles of the FTC and BTL. Differentially methylated sites between the two groups were identified and combined with data from gene expression profiles. A total of 80 differentially methylated sites were significant between FTC and BTL and 58 were inversely correlated with gene expressions. Both DNA methylation profiles and mRNA expression profiles based on unsupervised hierarchical clustering identified two unique clusters that had distinct signatures (Figures 2C, D). Figure 3A shows the result of integrated analysis of DNA methylation and mRNA expression in FTC vs. BTL.

**Candidate Methylation Sites**

According to the methods, 5 methylation sites were selected as candidate methylation sites. The methylation level of these candidate methylation sites between FTC and BTL were displayed in Figure 3B as a boxplot, which shows significant differences between the two groups. In addition, Figure 3C shows the result of the principal component analysis (PCA).
The samples gathered together within the same group and stayed away from the samples of different group. That means the candidate methylation sites performed well in distinguishing FTC from BTL.

**External Validation of Candidate Methylation Sites**

The five candidate methylation sites underwent pyrophosphoric acid sequencing to obtain the methylation level and only four of them were successfully evaluated. Then, ROC analysis was used to evaluate the diagnostic performance of each site on the discovery set and validation set respectively. As shown in Figure 4, all the four candidate sites were able to completely distinguish between the two sets of samples in the discovery set, with 100% sensitivity, specificity and AUC. In the validation set, the overall performance decreased, mainly due to the decrease in area under the curve, with the lowest AUC of only 0.53 (cg06447474); meanwhile, the specificity of each candidate site decreased, with the lowest specificity for cg06447474 and cg17874802, only 40%. However, the sensitivity of all candidate sites was high: cg06447474 90%, cg06928209 90%, cg17874802 100%, and cg17876578 100%. In summary, cg06928209 is the most promising of all candidate methylation sites as a molecular marker for early diagnosis, with 90% sensitivity, 80% specificity and AUC 0.77 on the external validation set.

**DISCUSSION**

The diagnosis of FTC before surgical resection remains challenging. Routine screening methods such as ultrasound or even FNAB could not diagnose FTC preoperatively. Accurate diagnosis may help to avoid unnecessary surgery in patient with benign thyroid lesions. Molecular tests were reported to be promising tools to aid pre-operative diagnosis of thyroid nodules, for example, a gene expression classifier based on 167 transcripts was tested in a multicentric study including 265 FNAB with indeterminate cytology (20). A high sensitivity (92%), but a low specificity (52%) was found in the identification of suspicious nodules. In this study, we analyzed DNA methylation and gene expression profiles in follicular thyroid cancer samples and benign thyroid lesion samples in our own cohort. One methylation site cg06928209 was identified as the potential biomarkers with high sensitivity and specificity in distinguishing FTC from BTL.

DNA methylation can effectively promote gene silencing and the hypermethylation status of CpG islands located in the promoter regions of tumor suppressor genes is thought to be the most common mechanism for inactivation of tumor suppressor genes in cancer development (21). Thus, detection of DNA methylation is thought to be a potentially effective screening means (22–28). RNA is a key component of gene transcription. However, from a biochemical point of view, both
RNA and proteins are less stable than their DNA counterparts, which makes DNA-based markers particularly attractive, especially for non-invasive screening through blood and other body fluids (25–27). Yim JH. et al. performed differential DNA methylation analysis in 109 post-thyroid surgery tissue samples and a new diagnostic classifier for thyroid nodules was identified, with a sensitivity of 100% and a specificity of 97%. However, the study lacked external validation sets to further validate its performance and there were no FTC samples in their cohort (29). Mateus C. et al. used 70 thyroid cancer samples (mostly composed of PTC) and 17 BTL as training sets and the results showed a sensitivity of 90.7% and specificity of 75.4% for distinguishing between thyroid malignancies in postoperative tissue samples (30). Yet, their study was designed to identify potential biomarkers distinguishing malignancies and benign lesions rather than FTC and benign lesions specifically. In our study, we focused on the ability of molecular markers to distinguish FTC from BTL, with a sensitivity of 90.0% and a specificity of 80.0%.

As reported in previous studies, promoter hypermethylation is associated with transcriptional silencing of genes. Thus, opposing direction of gene expression and methylation status change was taken into consideration for the integrative analysis. This kind of integrated analysis was used in multiple studies in the past. For example, Zhiming L. et al. identified the cg23478805 methylation site on the ZCCHC13 gene as a marker for non-obstructive azoospermia (31) and Poirier JT. et al. analyzed a specific subgroup in small cell lung cancer (32). The role of the CXCL12 gene and its degree of methylation in the development of PTC was explored by Zhang S. et al. (33). However, as far as we know, very few studies used the same method to analyze FTC samples.

The limitation of this study is the relatively small training set due to the difficulty in FTC sample collection. This problem was also observed in other studies. For example, Mateus C. et al. included 70 thyroid cancer samples, but only 10 of them were FTC. Secondly, changing the proportion of samples in training set and validation set may help to increase the power of this study. More samples in the training set while less samples in the validation set should reduce the possibility of false positive, thus, 20 samples in training set and 10 samples in testing set may be a better design. In addition, only nodular goiter samples were selected to represent benign nodules in this study, because nodular goiter is the most common type in clinical practice and often coexists with other types of benign nodules. A more systematic study on the preoperative molecular diagnosis of FTC and follicular adenoma is planned for further research work.

In addition, we also investigated the performance of all combinations of selected methylation sites using logistic regression models and. However, the result (Supplementary Table 2) shows no significant improvement compared to the single site. It gives us a clue that maybe more sophisticated approaches are needed to extract additional information of significant differential methylated sites rather than simply combinations. For instance, the k-Nearest Neighbors, Support Vector Machine, Convolutional Neural Network and other machine learning approaches. Indeed, some studies has reported using machine learning approaches in analysis of multi omics, for example Zhang et al. used this comprehensive method to combine micro-RNA profile and protein sequencing to detect biomarkers for Grave’s disease and orbitopathy (34).

In summary, the differential methylation site cg06928209 was identified in this study by integrated analysis of RNA expression profile and DNA methylation profile, which shows high sensitivity and specificity in distinguishing FTC from BTL and can be used as a potential diagnostic tool.

**CONCLUSION**

The four DNA methylation sites identified by this study, especially the cg06928209 site, can be used as a potential screening tool for detection and preoperative diagnosis of FTC patients. This assay has relatively high sensitivity and specificity, and is of great clinical value for the accurate diagnosis and treatment of thyroid nodules, especially for the identification of FTC and BTL by molecular means and the accurate preoperative diagnosis of FTC.
DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/), accession number GSE197861.

AUTHOR CONTRIBUTIONS

The research project was designed by YY, WW, and ZG, then organized by XFW, LT, and XL. Samples were collected by YY and XMW. Laboratory work was conducted by TY and YW. Data analysis and the confirmation of selected sites was conducted by PX and ZM. The first draft of the manuscript was written by YY, and the manuscript was reviewed by LS, WW, LT, and XL. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med (2016) 375(11):1054–67. doi: 10.1056/NEJMra1501993
2. Hegedüs L. The Thyroid Nodule. N Engl J Med (2004) 351(17):1764–71. doi: 10.1056/NEJMcp031436
3. Schneider DF, Chen H. New Developments in the Diagnosis and Treatment of Thyroid Cancer. CA: A Cancer J Clin (2013) 63(6):373–94. doi: 10.3322/caac.21195
4. Wang C-CC, Friedman L, Kennedy GC, Wang H, Kebebew E, Steward DL, et al. A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology. Thyroid (2010) 21(3):243–51. doi: 10.1089/thy.2010.0243
5. Yang J, Schmadig V, Logrono R, Wasserman PG. Fine-Needle Aspiration of Thyroid Nodules: A Study of 4703 Patients With Histologic and Clinical Correlations. Cancer Cytopathol (2007) 111(5):306–15. doi: 10.1002/cncr.22955
6. Filho JG, Kowalski LP. Surgical Complications After Thyroid Surgery Performed in a Cancer Hospital. Otolaryngol Head Neck Surg (2005) 132(3):490–4. doi: 10.1016/j.otohns.2004.09.028
7. Hundahl SA, Fleming ID, Fremgen AM, Mencik HR. A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U.S., 1985–1995 [See Comments]. Cancer (1998) 83(12):2638–48. doi: 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
8. Nakamura T, Kawai K, Hori Y, Nishio K, Hasegawa T, Kato Y, et al. Preoperative Diagnosis of Benign Thyroid Nodules With Indeterminate Cytology. Thyroid (2012) 22(8):935–40. doi: 10.1089/thy.2012.0164
9. Huang Y, Zhang P, Liu Y, Li Q, Wang T, Zhang Y, et al. DNA Methylation Site Mutations and Clinical Predictive Value of Prognosis in Papillary Thyroid Carcinoma. Cancer Cytopathol (2015) 123(10):716–23. doi: 10.1002/(SICI)1097-0241(201510)123:10<716::AID-CNCR3070>3.0.CO;2-0
10. Li W, Zhang X, Lu X, You L, Song Y, Luo Z, et al. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Human Cancers. Cell Res (2017) 27(10):1243–57. doi: 10.1038/cr.2017.121
11. Alexander EK, Schnieders C, Sipos J, Klotz L, Bucala R, Doppman JL, et al. Functional and Clinical Significance of DNA Methylation Site Mutations in Thyroid Cancer. Cancer Genet Cytogenet (2016) 212:255–265. doi: 10.1016/j.cgg.2016.08.005
12. Bui J, Sullivan KE, Rhee EK, Humphrey DS, Lee Y, Jang EJ, et al. Kallikrein Stepwise Scoring Reveals Three Subtypes of Papillary Thyroid Cancer With Prognostic Implications. Thyroid (2017) 28(5):601–12. doi: 10.1089/thy.2017.0501
13. Bissaro dos Reis M, Barros-Filho MC, Marchi FA, Kuasne H, Pinto CAL, et al. Integrated Data Analysis Reveals Potential Drivers and Pathways Disrupted by DNA Methylation in Papillary Thyroid Carcinomas. Clin Epigenet (2017) 9:45. doi: 10.1186/s13148-017-0346-2
14. Yang J, Schmadig V, Logrono R, Wasserman PG. Fine-Needle Aspiration of Thyroid Nodules: A Study of 4703 Patients With Histologic and Clinical Correlations. Cancer Cytopathol (2007) 111(5):306–15. doi: 10.1002/cncr.22955
15. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, et al. Multicenter Clinical Experience With the Afirma Gene Expression Classifier. J Clin Endocrinol Metab (2014) 99(1):119–25. doi: 10.1210/jc.2013-2482
16. Shakovskaya N, Zavitsanou A, Tsirka S, Ntimou G, Gouliou P, Hadziyianni M, et al. DNA Methylation-Based Biomarkers for Invasive Cancer Screening. Curr Mol Med (2013) 13(2):195–209. doi: 10.2174/156652413803030128
17. Jones PA, Baylin SB. The Fundamental Role of Epigenetic Events in Cancer. Nat Rev Genet (2002) 3(6):415–28. doi: 10.1038/nrg818
18. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. PLoS Med (2006) 3(12):e486. doi: 10.1371/journal.pmed.0030486
19. Verma M, Manne U. Genetic and Epigenetic Biomarkers in Cancer Diagnosis and Identifying High Risk Populations. Crit Rev Oncol Hematol (2006) 60(1):9–18. doi: 10.1016/j.critrevonc.2006.04.002
20. Fleischhacker M, Schmidt B. Circulating Nucleic Acids (CNAs) and Cancer—a Survey. Biochim Biophys Acta (2007) 1775(1):181–232. doi: 10.1016/j.bjba.2006.10.001
21. Levenson VV. Biomarkers for Early Detection of Breast Cancer: What, When, and Where? Biochim Biophys Acta (2007) 1770(6):847–56. doi: 10.1016/j.bjba.2007.01.017
22. Shames DS, Minna JD, Gazdar AF. DNA Methylation in Health, Disease, and Cancer. Curr Mol Med (2007) 7(1):85–102. doi: 10.2174/15665240779940413
23. Mulerio-Navarro S, Esteller M. Epigenetic Biomarkers for Human Cancer: The Time Is Now. Crit Rev Oncol Hematol (2008) 68(1):1–11. doi: 10.1016/j.critrevonc.2008.03.001

FUNDING

This study is supported by Grants from the National Natural Science Foundation of China (No. 81772853, 81972495, 81502786 and 81902719), Grants from National Natural Science Foundation of Zhejiang (No. LY18H160012, LQ18H120002 and LQ14H260003), and the Key Project of Scientific and Technological Innovation of Zhejiang Province (No. 2015C03031).

SUPPLEMENTARY MATERIAL

The Supplemental Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.736068/full#supplementary-material
29. Yim JH, Choi AH, Li AX, Qin H, Chang S, Tong S-WT, et al. Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res: Off J Am Assoc Cancer Res (2019) 25(2):544–51. doi: 10.1158/1078-0432.CCR-18-0841

30. Barros-Filho MC, Dos Reis MB, Beltrami CM, de Mello JB, Marchi FA, Kaasne H, et al. DNA Methylation-Based Method to Differentiate Malignant From Benign Thyroid Lesions. Thyroid (2019) 29(9):1244–54. doi: 10.1089/thy.2018.0458

31. Li Z, Chen S, Yang Y, Zhuang X, Tzeng CM. Novel Biomarker ZCCHC13 Revealed by Integrating DNA Methylation and mRNA Expression Data in Non-Obstructive Azoospermia. Cell Death Discov (2018) 4:36. doi: 10.1038/s41420-018-0033-x

32. Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, et al. DNA Methylation in Small Cell Lung Cancer Defines Distinct Disease Subtypes and Correlates With High Expression of EZH2. Oncogene (2015) 34 (48):5869–78. doi: 10.1038/onc.2015.38

33. Zhang S, Wang Y, Chen M, Sun L, Han J, Elena VK, et al. CXCL12 Methylation-Mediated Epigenetic Regulation of Gene Expression in Papillary Thyroid Carcinoma. Sci Rep (2017) 7:44033. doi: 10.1038/srep44033

34. Zhang L, Masetti G, Colucci G, Salvi M, Covelli D, Eckstein A, et al. Combining Micro-RNA and Protein Sequencing to Detect Robust Biomarkers for Graves’ Disease and Orbitopathy. Sci Rep (2018) 8(1):8386. doi: 10.1038/s41598-018-26700-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.